Michael R Freeman

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 12

Top Topics

Saccharomyces Cerevisiae

Top Venues

Prostate cancer and prostatic diseases

Nature medicine

Nature reviews. Urology

This page only lists publications with an associated author ORCID identifier.

Publications

Kai Li, Avradip Chatterjee, Chen Qian, Katherine Lagree, Y Oliver Wang, Courtney A Becker, Michael R Freeman, Ramachandran Murali, Wei Yang, David Michael Underhill
Profiling phagosome proteins identifies PD-L1 as a fungal-binding receptor. Nature 630 (8017) (2024)
Kai Li, Avradip Chatterjee, Chen Qian, Katherine Lagree, Y Oliver Wang, Courtney A Becker, Michael R Freeman, Ramachandran Murali, Wei Yang, David Michael Underhill
Profiling phagosome proteins identifies PD-L1 as a fungal-binding receptor. Nature 630 (8017) (2024)
Kai Li, Avradip Chatterjee, Chen Qian, Katherine Lagree, Y Oliver Wang, Courtney A Becker, Michael R Freeman, Ramachandran Murali, Wei Yang, David Michael Underhill
Profiling phagosome proteins identifies PD-L1 as a fungal-binding receptor. Nature 630 (8017) (2024)
Kai Li, Avradip Chatterjee, Chen Qian, Katherine Lagree, Y Oliver Wang, Courtney A Becker, Michael R Freeman, Ramachandran Murali, Wei Yang, David Michael Underhill
Profiling phagosome proteins identifies PD-L1 as a fungal-binding receptor. Nature (2024)
Kai Li, Avradip Chatterjee, Chen Qian, Katherine Lagree, Y Oliver Wang, Courtney A Becker, Michael R Freeman, Ramachandran Murali, Wei Yang, David Michael Underhill
Profiling phagosome proteins identifies PD-L1 as a fungal-binding receptor. Nature (2024)
Kai Li, Avradip Chatterjee, Chen Qian, Katherine Lagree, Y Oliver Wang, Courtney A Becker, Michael R Freeman, Ramachandran Murali, Wei Yang, David Michael Underhill
Profiling phagosome proteins identifies PD-L1 as a fungal-binding receptor. Nature 630 (8017) (2024)
Gloria Cecilia Galván, Everardo Macias, Sergio Sanders, Adela Ramirez-Torres, Shannon Stock, Sungyong You, Céline E Riera, Patrick Tamukong, Stephanie A Smith-Warner, Jeanine M Genkinger, Daniel J Luthringer, Michael R Freeman, Stephen J Freedland
The effects of glycemic index on prostate cancer progression in a xenograft mouse model. Prostate cancer and prostatic diseases (2023)
Jun Gong, Daniel M Kim, Michael R Freeman, Hyung Kim, Leigh Ellis, Bethany Smith, Dan Theodorescu, Edwin Posadas, Robert Figlin, Neil Bhowmick, Stephen J Freedland
Genetic and biological drivers of prostate cancer disparities in Black men. Nature reviews. Urology (2023)
Yiwu Yan, Bo Zhou, Chen Qian, Alex Vasquez, Mohini Kamra, Avradip Chatterjee, Yeon-Joo Lee, Xiaopu Yuan, Leigh Ellis, Dolores Di Vizio, Edwin M Posadas, Natasha Kyprianou, Beatrice S Knudsen, Kavita Shah, Ramachandran Murali, Arkadiusz Gertych, Sungyong You, Michael R Freeman, Wei Yang
Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis. Nature communications 13 (1) (2022)
Junhee Yoon, Minhyung Kim, Edwin M Posadas, Stephen J Freedland, Yang Liu, Elai Davicioni, Robert B Den, Bruce J Trock, R Jeffrey Karnes, Eric E Klein, Michael R Freeman, Sungyong You
A comparative study of PCS and PAM50 prostate cancer classification schemes. Prostate cancer and prostatic diseases 24 (3) (2021)
Lauren E Howard, Jingbin Zhang, Nick Fishbane, Amanda M De Hoedt, Zachary Klaassen, Daniel E Spratt, Adriana C Vidal, Dechen Lin, Megan P Hitchins, Sungyong You, Michael R Freeman, Kosj Yamoah, Elai Davicioni, Stephen J Freedland
Validation of a genomic classifier for prediction of metastasis and prostate cancer-specific mortality in African-American men following radical prostatectomy in an equal access healthcare setting. Prostate cancer and prostatic diseases 23 (3) (2019)
Mirja Rotinen, Sungyong You, Julie Yang, Simon G Coetzee, Mariana Reis-Sobreiro, Wen-Chin Huang, Fangjin Huang, Xinlei Pan, Alberto Yáñez, Dennis J Hazelett, Chia-Yi Chu, Kenneth Steadman, Colm M Morrissey, Peter S Nelson, Eva Corey, Leland W K Chung, Stephen J Freedland, Dolores Di Vizio, Isla P Garraway, Ramachandran Murali, Beatrice S Knudsen, Michael R Freeman
ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis. Nature medicine 24 (12) (2018)